This Week in Clinical Chemistry

Chris Pemberton from the University of Otago in New Zealand and his colleagues report in Clinical Chemistry that the prepro-A-type natriuretic peptide signal peptide could be a biomarker of cardiovascular disease. Pemberton and his colleagues developed an immunoassay for the preproANP signal peptide and used it to determine the concentrations of the peptide in healthy heart tissue, circulating in healthy volunteers, in heart attack patients, and in patients undergoing catheterization. In addition, they analyzed the circulating ANPsp by tandem mass spec. In the heart attack patients, the researchers found that "plasma concentrations of ANPsp rose to peak values at 5 h after symptom onset, significantly earlier than myoglobin, creatine kinase-MB, and troponin."

University of Washington researchers led by Tomas Vaisar write in Clinical Chemistry that "LC-MRM/MS could be used to replace immunoassays in a variety of settings." They used a shotgun proteomic approach, LC-MRM/MS, and commercially available immunoassays to analyze apoliporoteins A-I, C-II, C-III, E, B, and J. While the shotgun approach did not correlate well with the immunoassay findings, the LC-MRM/MS approach did, the researchers found.